Categories
Change Password!
Reset Password!
To describe the allergy work-up protocol executed for the vaccination campaign, promoting safe vaccination in large population.
This study comprising
of 4042 vaccine population found that the use of an precise protocol for the
identification and management of people prone to allergic reactions to the
SARS151 CoV-2 vaccine can permit safe vaccination in possibly high risk people,
consequently coping reluctance due to vaccine in allergy sufferers.
To describe the
allergy work-up protocol executed for the vaccination campaign, promoting safe
vaccination in large population.
Past alleged
allergies linked with drug or vaccine, and consequent teleconsultation and
allergometric tests for polyethylene glycol (PEG) and Polysorbate 80 (PS80)
were presented in a self-report. A desensitizing protocol of vaccine
administration was used to patients sensitized only to PS80, and to those with
a suspect allergic reaction following the initial dose.
Out of 4042 vaccine
population, 10.2% (414) have been screened: only 1 patient was found allergic
to PEG and hence, dismissed from the vaccination. Another patient was allergic
to PS80 only and safely vaccinated using the desensitizing protocol. 7 subjects
without a allergic disease in the past suffered suspect hypersensitivity
reactions to the initial dose: 1 of them was allergic to PEG and was dismissed
from the second dose, whereas the others were successful in completing the
vaccination safely using desensitizing protocol.
The use of meticulous
allergological risk-assessment protocol can significantly decrease the number
of patients who would have eluded COVID-19 vaccination for their allergies. It
can also help in effective identification and management of atypical patients
sensitized to PEGs and/or PS80.
The World Allergy Organization Journal
Successful SARS-CoV-2 vaccine allergy risk-management: the experience of a large Italian University Hospital
Giovanni Paoletti et al.
Comments (2)